WO2024134541 - HETEROCYCLIC COMPOUNDS AS ENT INHIBITORS AND COMPOUNDS FOR USE IN THE TREATMENT OF CANCERS
National phase entry is expected:
Publication Number
WO/2024/134541
Publication Date
27.06.2024
International Application No.
PCT/IB2023/063020
International Filing Date
20.12.2023
Title **
[English]
HETEROCYCLIC COMPOUNDS AS ENT INHIBITORS AND COMPOUNDS FOR USE IN THE TREATMENT OF CANCERS
[French]
COMPOSÉS HÉTÉROCYCLIQUES UTILISÉS EN TANT QU'INHIBITEURS D'ENT ET COMPOSÉS DESTINÉS À ÊTRE UTILISÉS DANS LE TRAITEMENT DE CANCERS
Applicants **
ITEOS BELGIUM SA
Inventors
DELIGNY, Michael
VAN DER PLAS, Steven
HOUTHUYS, Erica Joke Katelijne Heleen
ROWLEY, Michael
Priority Data
63/476,194
20.12.2022
US
63/609,006
12.12.2023
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 11498 | |
| EPO | Filing, Examination, Granting | 58945 | |
| Japan | Filing, Examination, Granting | 3575 | |
| South Korea | Filing, Examination, Granting | 4861 | |
| USA | Filing, Examination, Granting | 21140 |
Total:
100,019
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
The present disclosure relates to certain heterocyclic compounds, including compounds of Formula (I): (I) or pharmaceutically acceptable salts, hydrates, or solvates thereof. The disclosure further relates to the use of the compounds disclosed as inhibitors of equilibrative nucleoside transporters (ENTs). The disclosure also relates to the use of the compounds disclosed for the treatment and/or prevention of cancer.[French]
La présente divulgation concerne certains composés hétérocycliques, comprenant des composés de formule (I) : (I) ou des sels, des hydrates ou des solvates pharmaceutiquement acceptables de ceux-ci. La divulgation concerne en outre l'utilisation des composés divulgués en tant qu'inhibiteurs de transporteurs de nucléosides équilibrés (ENT). La divulgation concerne également l'utilisation des composés divulgués pour le traitement et/ou la prévention du cancer.